{"id":5957,"date":"2026-10-19T09:48:14","date_gmt":"2026-10-19T09:48:14","guid":{"rendered":"https:\/\/phd.hi.is\/doktorsvorn\/doktorsvorn-i-lyfjafraedi-2\/"},"modified":"2026-10-19T09:48:14","modified_gmt":"2026-10-19T09:48:14","slug":"doktorsvorn-i-lyfjafraedi-2","status":"publish","type":"phd_defence","link":"https:\/\/phd.hi.is\/en\/doktorsvorn\/doktorsvorn-i-lyfjafraedi-2\/","title":{"rendered":"Doktorsv\u00f6rn \u00ed lyfjafr\u00e6\u00f0i"},"content":{"rendered":"<div class=\"field-items\">\n<div class=\"field-item even\" property=\"content:encoded\">\n<p>Sunna J\u00f3hannsd\u00f3ttir ver doktorsritger\u00f0 s\u00edna \u00ed lyfjafr\u00e6\u00f0i vi\u00f0 Lyfjafr\u00e6\u00f0ideild H\u00e1sk\u00f3la \u00cdslands. Ritger\u00f0in ber heiti\u00f0: S\u00fdkl\u00f3dextr\u00edn\u00f6ragnir sem augnlyfjaferjur fyrir litlar lyfjasameindir, pept\u00ed\u00f0 og pr\u00f3tein. Cyclodextrin nanoparticles in ocular drug delivery for small molecular weight drugs as well as for peptide and protein drugs. \u00a0 \u00a0 \u00a0 \u00a0 <\/p>\n<p>Andm\u00e6lendur eru dr. Lajos Szente, framkv\u00e6mdastj\u00f3ri CycloLab Ltd \u00ed Ungverjalandi, og dr. Sveinbj\u00f6rn Gizurarson, pr\u00f3fessor vi\u00f0 Lyfjafr\u00e6\u00f0ideild H\u00e1sk\u00f3la \u00cdslands. <\/p>\n<p>Umsj\u00f3narkennari og lei\u00f0beinandi var dr. \u00deorsteinn Loftsson, pr\u00f3fessor vi\u00f0 Lyfjafr\u00e6\u00f0ideild. A\u00f0 auki s\u00e1tu \u00ed doktorsnefnd Einar Stef\u00e1nsson, pr\u00f3fessor vi\u00f0 L\u00e6knadeild, Au\u00f0ur Magn\u00fasd\u00f3ttir, deildarforseti vi\u00f0 Landb\u00fana\u00f0arh\u00e1sk\u00f3la \u00cdslands, dr. H\u00e1kon Hrafn Sigur\u00f0sson, pr\u00f3fessor og deildarforseti vi\u00f0 Lyfjafr\u00e6\u00f0ideild, og dr. Kim Lambertsen Larsen, d\u00f3sent vi\u00f0 \u00c1laborgarh\u00e1sk\u00f3la. <\/p>\n<p>Dr. H\u00e1kon Hrafn Sigur\u00f0sson, pr\u00f3fessor og forseti Lyfjafr\u00e6\u00f0ideildar, stj\u00f3rnar ath\u00f6fninni.<\/p>\n<p>\u00c1grip af ranns\u00f3kn <br \/>Verkefni\u00f0 fjallar um h\u00f6nnun augndropa sem innihalda hj\u00e1lparefni\u00f0 s\u00fdkl\u00f3dextr\u00edn. Lyfjame\u00f0h\u00f6ndlun augnsj\u00fakd\u00f3ma getur reynst erfi\u00f0 vegna fl\u00f3kinna l\u00edfe\u00f0lisfr\u00e6\u00f0ilegra eiginleika augans. Ef hef\u00f0bundin lyfjagj\u00f6f, \u00fe.e. \u00ed formi augndropa, \u00e1 a\u00f0 reynast \u00e1rangursr\u00edk \u00fearf lyfi\u00f0 a\u00f0 b\u00faa b\u00e6\u00f0i yfir vatnsleysanlegum eiginleikum, svo lyfi\u00f0 komist yfir t\u00e1rav\u00f6kvann a\u00f0 yfirbor\u00f0i augans, og fituleysanlegum eiginleikum, til a\u00f0 fr\u00e1sogast yfir vefi augans. Varnareiginleikar augans, aukin t\u00e1raframlei\u00f0sla og t\u00ed\u00f0ni blikka, gera \u00fea\u00f0 a\u00f0 verkum a\u00f0 lyfi\u00f0 n\u00e6r einungis a\u00f0 haldast \u00e1 auganu \u00ed stuttan t\u00edma \u00e1\u00f0ur en \u00fev\u00ed er skola\u00f0 \u00ed burtu en \u00fea\u00f0 lei\u00f0ir til minna fr\u00e1sogs lyfsins. \u00a0 <br \/>S\u00fdkl\u00f3dextr\u00edn eru hj\u00e1lparefni sem notu\u00f0 eru vi\u00f0 lyfjager\u00f0 til a\u00f0 auka leysanleika og st\u00f6\u00f0ugleika lyfja \u00ed vatni. S\u00fdkl\u00f3dextr\u00edn geta mynda\u00f0 fl\u00e9ttur vi\u00f0 fitus\u00e6kin torleysanleg lyf og auki\u00f0 leysni \u00feeirra, en fl\u00e9tturnar geta h\u00f3pa\u00f0 sig saman og mynda\u00f0 nan\u00f3agnir. \u00a0 <br \/>\u00cd verkefninu var leitast vi\u00f0 a\u00f0 s\u00fdna hvernig dexametas\u00f3n (augnlyf) \u00ed s\u00fdkl\u00f3dextr\u00edn\/dexametas\u00f3n nan\u00f3\u00f6gnum berst fr\u00e1 yfirbor\u00f0i augans til bakhluta \u00feess \u00ed kan\u00ednum, en sl\u00edk lyfjaferja g\u00e6ti t.d. komi\u00f0 \u00ed sta\u00f0 inngripsmeiri lyfjagjafa me\u00f0 sprautu. <br \/>\u00de\u00e1 fjallar verkefni\u00f0 einnig um \u00fer\u00f3un s\u00fdkl\u00f3spor\u00edn augnlyfs (pept\u00ed\u00f0 lyf) me\u00f0 notkun s\u00f6mu t\u00e6kni og \u00e1\u00f0ur hefur veri\u00f0 l\u00fdst auk pr\u00f3funar \u00feess \u00e1 kan\u00ednum. A\u00f0 lokum fjallar verkefni\u00f0 un \u00fer\u00f3un l\u00fds\u00f3s\u00fdm (pr\u00f3tein) augndropa, en ekki reyndist unnt a\u00f0 nota \u00e1\u00f0urnefnda t\u00e6kni vi\u00f0 \u00fer\u00f3un sl\u00edkra augndropa. <\/p>\n<p>Um doktorsefni\u00f0 <br \/>Sunna J\u00f3hannsd\u00f3ttir er f\u00e6dd 1985. H\u00fan lauk BS-gr\u00e1\u00f0u \u00ed lyfjafr\u00e6\u00f0i fr\u00e1 H\u00e1sk\u00f3la \u00cdslands \u00e1ri\u00f0 2009 og MS-gr\u00e1\u00f0u \u00ed lyfjafr\u00e6\u00f0i fr\u00e1 sama sk\u00f3la \u00feremur \u00e1rum s\u00ed\u00f0ar. Sunna starfar hj\u00e1 Oculis Pharma ehf. og samb\u00fdlisma\u00f0ur hennar er \u00cdvar M\u00e1r Ottason.<\/p>\n<\/div><\/div>","protected":false},"featured_media":1102,"template":"","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_phd_date_start":"2017-11-22T13:00:00+00:00","_phd_date_end":"2017-11-22T16:00:00+00:00","_phd_location":"A\u00f0albygging H\u00e1t\u00ed\u00f0asal","_phd_admission":"A\u00f0gangur \u00f3keypis","_phd_thesis_title":"S\u00fdkl\u00f3dextr\u00edn\u00f6ragnir sem augnlyfjaferjur fyrir litlar lyfjasameindir, pept\u00ed\u00f0 og pr\u00f3tein. Cyclodextrin nanoparticles in ocular drug delivery for small molecular weight drugs as well as for peptide and protein drugs","_phd_source_url":"https:\/\/gamli.hi.is\/vidburdir\/doktorsvorn_i_lyfjafraedi_0","_phd_source_node_id":"309081","_phd_source_type":"vidburdir","_phd_member_id":108,"footnotes":""},"phd_school":[60,64],"phd_discipline":[66],"class_list":["post-5957","phd_defence","type-phd_defence","status-publish","has-post-thumbnail","hentry","phd_school-heilbrigdisvisindasvid","phd_school-lyfjafraedideild","phd_discipline-phd-i-lyfjafraedi"],"_links":{"self":[{"href":"https:\/\/phd.hi.is\/en\/wp-json\/wp\/v2\/phd_defence\/5957","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/phd.hi.is\/en\/wp-json\/wp\/v2\/phd_defence"}],"about":[{"href":"https:\/\/phd.hi.is\/en\/wp-json\/wp\/v2\/types\/phd_defence"}],"version-history":[{"count":0,"href":"https:\/\/phd.hi.is\/en\/wp-json\/wp\/v2\/phd_defence\/5957\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/phd.hi.is\/en\/wp-json\/wp\/v2\/media\/1102"}],"wp:attachment":[{"href":"https:\/\/phd.hi.is\/en\/wp-json\/wp\/v2\/media?parent=5957"}],"wp:term":[{"taxonomy":"phd_school","embeddable":true,"href":"https:\/\/phd.hi.is\/en\/wp-json\/wp\/v2\/phd_school?post=5957"},{"taxonomy":"phd_discipline","embeddable":true,"href":"https:\/\/phd.hi.is\/en\/wp-json\/wp\/v2\/phd_discipline?post=5957"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}